SIRT1在肝脏疾病中的作用及研究进展

doi:10.3870/j.issn.1672-8009.2026.03.010

摘要/Abstract

摘要： 沉默信息调节因子1(silent information regulator 1,SIRT1)是Sirtuin家族的核心成员,作为一种依赖NAD⁺的Ⅲ型组蛋白去乙酰化酶,在表观遗传调控网络中占据重要地位。SIRT1通过去乙酰化修饰多种组蛋白及非组蛋白底物,广泛调控脂质代谢、氧化应激、炎症反应和细胞凋亡等关键生理过程。目前研究表明,SIRT1的表达失调或功能缺陷与肝脏疾病的发生发展密切相关。文章总结了SIRT1在酒精相关性肝病、代谢功能障碍相关脂肪性肝病、病毒性肝炎、肝纤维化以及肝细胞癌中的作用机制。同时,对SIRT1靶向干预在慢性肝病治疗中的应用进行了简要介绍,以期更深入理解其特异的调控机制,并为开发更精准的治疗策略提供理论依据。

关键词: 沉默信息调节因子1, 酒精相关性肝病, 代谢功能障碍相关脂肪性肝病, 肝纤维化, 病毒性肝炎, 肝细胞癌

Abstract: Silent information regulator 1(SIRT1),a core member of the Sirtuin family,is an NAD⁺-dependent class Ⅲ histone deacetylase that plays a crucial role in the epigenetic regulatory network.By mediating the deacetylation of a variety of histone and non-histone substrates,SIRT1 broadly regulates key physiological processes such as lipid metabolism,oxidative stress,inflammatory response,and apoptosis.Current studies indicate that dysregulation or functional impairment of SIRT1 is closely associated with the occurrence and progression of liver diseases.This article summarizes the specific mechanisms of SIRT1 in alcohol-associated liver disease,metabolic dysfunction-associated steatotic liver disease,viral hepatitis,liver fibrosis,and hepatocellular carcinoma.Additionally,the potential applications of SIRT1-targeted interventions in the treatment of chronic liver diseases are briefly discussed,with the aim of providing deeper insights into its unique regulatory mechanisms and offering a theoretical basis for developing more precise therapeutic strategies.

Key words: silent information regulator 1, alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, liver fibrosis, viral hepatitis, hepatocellular carcinoma

中图分类号:

R575

李玎嘉, 张钰婷, 刘亮明. SIRT1在肝脏疾病中的作用及研究进展[J]. 医学分子生物学杂志, 2026, 23(3): 308-315.

LI Dingjia, ZHANG Yuting, LIU Liangming. Research Progress on Roles of SIRT1 in Hepatic Diseases[J]. Journal of Medical Molecular Biology, 2026, 23(3): 308-315.

参考文献

[1] YANG Y,LIU Y,WANG Y,et al.Regulation of SIRT1 and its roles in inflammation[J].Front Immunol,2022,13:831168.
[2] SHEN S,SHEN M,KUANG L,et al.SIRT1/SREBPs-mediated regulation of lipid metabolism[J].Pharmacol Res,2024,199:107037.
[3] ZHANG C,ZHONG T,LI Y,et al.The hepatic AMPK-TET1-SIRT1 axis regulates glucose homeostasis[J].eLife,2021,10:e70672.
[4] 王道,陈建林,刘文彬,等.人SIRT1基因启动子及蛋白的生物信息学分析[J].激光生物学报,2023,32(4):368-384.
WANG D,CHEN J L,LIU W B,et al.Bioinformatics analysis of human SIRT1 gene promoter and encoding protein[J].Acta Laser Biol Sin,2023,32(4):368-384.
[5] ZUO F,YANG J,WU Q,et al.SIRT1 in liver diseases:Mechanistic insights and therapeutic prospects[J].Int J Biol Sci,2025,21(15):7086-7103.
[6] SHARMA A,MAHUR P,MUTHUKUMARAN J,et al.Shedding light on structure,function and regulation of human sirtuins:a comprehensive review[J].3 Biotech,2023,13(1):29.
[7] SUN L,FANG J.Macromolecular crowding effect is critical for maintaining SIRT1’s nuclear localization in cancer cells[J].Cell Cycle,2016,15(19):2647-2655.
[8] ZHANG H,WU D,WU Q,et al.The role of hepatic SIRT1:From metabolic regulation to immune modulation and multi-target therapeutic strategies[J].J Clin Transl Hepatol,2025,13(10):878-898.
[9] VARGHESE B,CHIANESE U,CAPASSO L,et al.SIRT1 activation promotes energy homeostasis and reprograms liver cancer metabolism[J].J Transl Med,2023,21(1):627.
[10] ZHANG R,ZHANG Q,CUI Z,et al.Regulatory role of sirtuin-1 by targeting MDM2 to mitochondria-associated membranes formation in the treatment of NAFLD[J].Cell Commun Signal,2025,23(1):514.
[11] TIAN L,CHEN J,YANG M,et al.Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway[J].Phytomedicine,2024,131:155776.
[12] HE S,WANG Y,LIU J,et al.Activating SIRT1 deacetylates NF-κB p65 to alleviate liver inflammation and fibrosisviainhibiting NLRP3 pathway in macrophages[J].Int J Med Sci,2023,20(4):505-519.
[13] WANG M,ZHAO J,CHEN J,et al.The role of sirtuin1 in liver injury:Molecular mechanisms and novel therapeutic target[J].PeerJ,2024,12:e17094.
[14] SON Y,HAN M,WU X,et al.SIRT1-mediated redox and senescence regulation in cancer:Mechanisms and therapeutic implications[J].Antioxidants(Basel),2025,14(9):1076.
[15] ZHANG Y,GONG C,TAO L,et al.Involvement of SIRT1-mediated aging in liver diseases[J].Front Cell Dev Biol,2025,13:1548015.
[16] ALVES-FERNANDES D K,JASIULIONIS M G.The role of SIRT1 on DNA damage response and epigenetic alterations in cancer[J].Int J Mol Sci,2019,20(13):3153.
[17] HAN X,LEI Q,XIE J,et al.Potential regulators of the senescence-associated secretory phenotype during senescence and aging[J].J Gerontol A Biol Sci Med Sci,2022,77(11):2207-2218.
[18] RAMATCHANDIRIN B,PEARAH A,HE L.Regulation of liver glucose and lipid metabolism by transcriptional factors and coactivators[J].Life(Basel),2023,13(2):515.
[19] MACKOWIAK B,FU Y,MACCIONI L,et al.Alcohol-associated liver disease[J].J Clin Investig,2024,134(3):e176345.
[20] REN R,WANG Z,WU M,et al.Emerging roles of SIRT1 in alcoholic liver disease[J].Int J Biol Sci,2020,16(16):3174-3183.
[21] PANG J,YIN L,JIANG W,et al.Sirt1-mediated deacetylation of PGC-1α alleviated hepatic steatosis in type 2 diabetes mellitusviaimproving mitochondrial fatty acid oxidation[J].Cell Signal,2024,124:111478.
[22] JIANG M,FENG Y,WANG J,et al.Saikogenin A improves ethanol-induced liver injury by targeting SIRT1 to modulate lipid metabolism[J].Commun Biol,2024,7(1):1547.
[23] YOU M,JOGASURIA A,TAYLOR C,et al.Sirtuin 1 signaling and alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr,2015,4(2):88-100.
[24] GUAN G,CHEN Y,DONG Y.Unraveling the AMPK-SIRT1-FOXO pathway:The in-depth analysis and breakthrough prospects of oxidative stress-induced diseases[J].Antioxidants(Basel),2025,14(1):70.
[25] THOUDAM T,GAO H,JIANG Y,et al.Mitochondrial quality control in alcohol-associated liver disease[J].Hepatol Commun,2024,8(11):e0534.
[26] DE GREGORIO E,COLELL A,MORALES A,et al.Relevance of SIRT1-NF-κB axis as therapeutic target to ameliorate inflammation in liver disease[J].Int J Mol Sci,2020,21(11):3858.
[27] MA Q,HUANG S,LI M Y,et al.Dihydromyricetin regulates the miR-155-5 p/SIRT1/VDAC1 pathway to promote liver regeneration and improve alcohol-induced liver injury[J].Phytomedicine,2025,139:156522.
[28] LI Y,YANG P,YE J,et al.Updated mechanisms of MASLD pathogenesis[J].Lipids Health Dis,2024,23(1):117.
[29] FAIENZA M F,FARELLA I,KHALIL M,et al.Converging pathways between metabolic dysfunction-associated steatotic liver disease(MASLD)and diabetes in children[J].Int J Mol Sci,2024,25(18):9924.
[30] VIDAL-CEVALLOS P,SORROZA-MARTÍNEZ A P,CHÁVEZ-TAPIA N C,et al.The relationship between pathogenesis and possible treatments for the MASLD-cirrhosis spectrum[J].Int J Mol Sci,2024,25(8):4397.
[31] ZHANG W,REN H,CHEN W,et al.Nicotinamide phosphoribosyltransferase in NAD⁺ metabolism:Physiological and pathophysiological implications[J].Cell Death Discov,2025,11(1):371.
[32] CHOI S E,FU T,SEOK S,et al.Elevated microRNA-34 a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT[J].Aging Cell,2013,12(6):1062-1072.
[33] 赵娟,尚文斌,于希忠.Sirt1及其相关信号通路蛋白调节胰岛素敏感性的研究进展[J].生命科学研究,2014,18(4):372-376.
ZHAO J,SHANG W B,YU X Z.Research progresses on Sirt1 and its responsive signal pathway proteins in regulation of insulin sensitivity[J].Life Sci Res,2014,18(4):372-376.
[34] SMITH G I,SHANKARAN M,YOSHINO M,et al.Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J].J Clin Invest,2020,130(3):1453-1460.
[35] ZHANG Y,REN L,TIAN Y,et al.Signaling pathways that activate hepatic stellate cells during liver fibrosis[J].Front Med,2024,11:1454980.
[36] LI J,ZHAO L,XI Y,et al.Resolvin D1 alleviates liver inflammation and fibrosis through SIRT1-mediated NF-κB and TGF-β1/Smads pathways[J].J Inflamm,2026,23(1):9.
[37] HUANG X Z,WEN D,ZHANG M,et al.Sirt1 activation ameliorates renal fibrosis by inhibiting the TGF-β/Smad3 pathway[J].J Cell Biochem,2014,115(5):996-1005.
[38] SUN M,WU X,LIN Z,et al.Investigation of HO-1 regulation of liver fibrosis related to nonalcoholic fatty liver disease through the SIRT1/TGF-β/Smad3 pathway[J].J Clin Transl Hepatol,2025,13(6):456-468.
[39] SUN L,FAN Z,CHEN J,et al.Transcriptional repression of SIRT1 by protein inhibitor of activated STAT 4(PIAS4)in hepatic stellate cells contributes to liver fibrosis[J].Sci Rep,2016,6:28432.
[40] LI M,HONG W,HAO C,et al.Hepatic stellate cell-specific deletion of SIRT1 exacerbates liver fibrosis in mice[J].Biochim Biophys Acta Mol Basis Dis,2017,1863(12):3202-3211.
[41] ZHANG F,KONG D,LU Y,et al.Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis:From bench to bedside[J].Cell Mol Life Sci,2013,70(2):259-276.
[42] YUAN H,XU R,LI S,et al.The malignant transformation of viral hepatitis to hepatocellular carcinoma:Mechanisms and interventions[J].MedComm,2025,6(3):e70121.
[43] KONG F,LI Q,ZHANG F,et al.Sirtuins as potential therapeutic targets for hepatitis B virus infection[J].Front Med,2021,8:751516.
[44] LI X,TANG Q,LONG Y,et al.Inhibiting silencing information regulator 1 is conducive to the suppression of hepatitis B virus replication by entecavir[J].J Pharmacol Exp Ther,2025,392(11):103740.
[45] SUN L J,LI S C,ZHAO Y H,et al.Silent information regulator 1 inhibition induces lipid metabolism disorders of hepatocytes and enhances hepatitis C virus replication[J].Hepatol Res,2013,43(12):1343-1351.
[46] SUN Z,WANG Y,JIN X,et al.Crosstalk between dysfunctional mitochondria and proinflammatory responses during viral infections[J].Int J Mol Sci,2024,25(17):9206.
[47] YU J W,SUN L J,LIU W,et al.Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway[J].Int J Infect Dis,2013,17(7):e539-e545.
[48] HERKER E.Lipid droplets in virus replication[J].FEBS Lett,2024,598(10):1299-1300.
[49] WEI K,PENG C,OU Y,et al.Decoding hepatocellular carcinoma metastasis:Molecular mechanisms,targeted therapies,and potential biomarkers[J].Curr Issues Mol Biol,2025,47(4):263.
[50] FENG L,CHEN M,LI Y,et al.Sirt1 deacetylates and stabilizes p62 to promote hepato-carcinogenesis[J].Cell Death Dis,2021,12(4):405.
[51] GUO S,LI F,LIANG Y,et al.AIFM2 promotes hepatocellular carcinoma metastasis by enhancing mitochondrial biogenesis through activation of SIRT1/PGC-1α signaling[J].Oncogenesis,2023,12(1):46.
[52] DU G,YANG R,QIU J,et al.Multifaceted influence of histone deacetylases on DNA damage repair:Implications for hepatocellular carcinoma[J].J Clin Transl Hepatol,2023,11(1):231-243.
[53] TANG Y,JU W,LIU Y,et al.The role of SIRT1 in autophagy and drug resistance:Unveiling new targets and potential biomarkers in cancer therapy[J].Front Pharmacol,2024,15:1469830.
[54] CHAN H Y,RAMASAMY T S,CHUNG F F,et al.Role of sirtuin 1(SIRT1)in regulation of autophagy and nuclear factor-kappa Beta(NF-κβ)pathways in sorafenib-resistant hepatocellular carcinoma(HCC)[J].Cell Biochem Biophys,2024,82(2):959-968.
[55] WANG N,DUAN Z,CHEN Z,et al.HBx inhibits the ferroptosis in HBV-associated hepatocellular carcinoma through upregulation of SIRT1[J].J Appl Toxicol,2026,46(5):1520-1529.
[56] ZHANG H,YUAN F,ZHAO N,et al.Nanoparticle-mediated SIRT1 inhibition suppresses M2 macrophage polarization and hepatocarcinogenesis in chronic hepatitis B[J].J Nanobiotechnology,2025,23(1):385.
[57] DING G,HUA H,LIU H,et al.The tumor suppressor protein menin inhibits NF-κB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma[J].Mol Biol Rep,2013,40(3):2461-2466.
[58] WU Q,WANG Y,QIAN M,et al.Sirt1 suppresses Wnt/βCatenin signaling in liver cancer cells by targeting βCatenin in a PKAα-dependent manner[J].Cell Signal,2017,37:62-73.
[59] LIU W M,ZHANG Q Q,MA H Q,et al.S-adenosylmethionine and nicotinic acid suppress Hepatocellular carcinoma proliferation by targeting SLC25 A4[J].Biochem Pharmacol,2026,243(Pt 2):117530.
[60] FARCAS M,GAVREA A A,GULEI D,et al.SIRT1 in the development and treatment of hepatocellular carcinoma[J].Front Nutr,2019,6:148.
[61] ZHRA M,ELAHI M A,TARIQ A,et al.Sirtuins and gut microbiota:Dynamics in health and a journey from metabolic dysfunction to hepatocellular carcinoma[J].Cells,2025,14(6):466.
[62] ZHUGE H,PAN Y,LAI S,et al.Penthorum chinense Pursh extract ameliorates alcohol-related fatty liver disease in mice via the SIRT1/AMPK signaling axis[J].Heliyon,2024,10(11):e31195.
[63] QI X,PAN M,FENG W,et al.Curcumol ameliorates alcoholic liver disease through regulation of SIRT1 signaling pathway[J].Eur J Pharmacol,2025,1008:178360.
[64] FU J,DENG W,GE J,et al.Sirtuin 1 alleviates alcoholic liver disease by inhibiting HMGB1 acetylation and translocation[J].PeerJ,2023,11:e16480.
[65] ELMORSY E A,ELSISI H A,ALKHAMISS A S,et al.Activation of SIRT1 by SRT1720 alleviates dyslipidemia,improves insulin sensitivity and exhibits liver-protective effects in diabetic rats on a high-fat diet:New insights into the SIRT1/Nrf2/NFκB signaling pathway[J].Eur J Pharm Sci,2025,206:107002.
[66] HAWARY O A,WADIE W,EL-SAID Y A M,et al.Repurposing of semaglutide by targeting SIRT1 and TGF‐β/Smad signaling in hepatic fibrosis[J].Naunyn Schmiedeberg’s Arch Pharmacol,2026,399(3):4413-4425.9